Personalis’ MRD test receives Medicare coverage in lung cancer surveillance

Personalis (PSNL) announced Medicare coverage for the company’s NeXT Personal molecular residual disease, or MRD, test for surveillance of patients with Stage I to III non-small cell lung cancer, or NSCLC. This coverage determination is grounded in clinical evidence generated through the company’s collaboration with the TRACERx consortium. Data from this world-renowned longitudinal study, recently published in Cell, demonstrated NeXT Personal’s ability to identify residual disease with high accuracy, validating the test’s clinical performance in lung cancer. NeXT Personal leverages whole-genome sequencing and advanced noise-suppression technology to achieve ultrasensitivity by tracking up to ~1800 mutations that represent a unique fingerprint of a patient’s tumor.